Cereno Scientific
Logotype for Cereno Scientific

Cereno Scientific (CRNO) investor relations material

Cereno Scientific Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Cereno Scientific
Q3 2026 earnings summary4 Nov, 2026

Executive summary

  • Three differentiated programs advanced: CS1 in Phase IIb for PAH, CS014 preparing for Phase IIb in PH-ILD, and preclinical CS585 targeting rare thrombotic diseases.

  • Positive CS014 PK bridging results supported a proposed direct path toward Phase IIb, subject to FDA review; EPIMODE site activation and patient recruitment readiness continued.

Financial highlights

  • Q3 2026 operating loss was SEK 17.9m versus SEK 13.5m in Q3 2025; loss after financial items was SEK 27.4m versus SEK 21.3m.

  • 9M 2026 operating loss was SEK 58.8m versus SEK 47.4m; loss after financial items was SEK 86.5m versus SEK 73.0m.

  • Cash and cash equivalents were SEK 40.2m at September 30, 2026, versus SEK 74.2m a year earlier; equity ratio was 47.6% versus 49.5%.

Outlook and guidance

  • EPIMODE targets up to 15 activated sites by end-2026 and more than half of planned sites by end-Q1 2027; recruitment completion is targeted during 2027 and topline results in Q4 2028, subject to recruitment timelines.

  • CS014 IND submission is planned for Q4 2026 and Phase IIb initiation for Q3 2027, subject to regulatory approval and completion of preparations.

  • Additional capital will be needed to execute development plans at the intended pace; financing and partnership options remain under evaluation.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Cereno Scientific earnings date

Logotype for Cereno Scientific
Q4 202617 Feb, 2027
Cereno Scientific
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Cereno Scientific earnings date

Logotype for Cereno Scientific
Q4 202617 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Cereno Scientific is a biotechnology company developing epigenetic therapies for cardiovascular and rare diseases. The company focuses on compounds that modulate endogenous defense mechanisms, with applications in thrombosis and inflammation. It operates in preclinical and clinical research stages. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the STO.